AN2 Therapeutics (ANTX) Change in Cash (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Change in Cash data on file, last reported at $33.5 million in Q1 2026.

• On a quarterly basis, Change in Cash rose 2555.78% year-over-year to $33.5 million in Q1 2026; TTM through Mar 2026 was $33.5 million, a 811.6% increase from a year earlier, with the FY2025 full-year figure at -$1.4 million, down 124.72% from the prior year.
• Change in Cash for Q1 2026 stood at $33.5 million, up from $1.9 million in the prior quarter.
• Over the last five years, Change in Cash for ANTX reached as high as $70.4 million in Q1 2022 and fell as low as -$41.9 million in Q2 2022.
• Historically, Change in Cash has averaged $2.4 million across 5 years, with a median of -$510000.0 in 2023.
• Across the five-year window, Change in Cash plunged 971.95% in 2023 and jumped 2555.78% in 2026, its largest moves.
• Year by year, Change in Cash stood at -$1.6 million in 2022, then plunged by 971.95% to -$17.0 million in 2023, then increased by 28.38% to -$12.2 million in 2024, then soared by 115.95% to $1.9 million in 2025, then surged by 1630.96% to $33.5 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were $33.5 million in Q1 2026, $1.9 million in Q4 2025, and -$217000.0 in Q3 2025.